Table 4.
Median SARS-CoV-2-reactive IgG antibody levels according to the development of breakthrough infection in ASCT and allo-HSCT recipients.
| Variables | SARS-CoV-2 infection | No infection | P value |
|---|---|---|---|
| Allo-HSCT | |||
| SARS-CoV-2-S-RA at 3-6 weeks (n = 315) | 45 | 270 | |
| • Median Ab titers in BAU/mL (range) | 57 (0–5714) | 2191 (0–40000) | 0.018 |
| SARS-CoV-2-S-RA at 3 months (n = 240) | 22 | 218 | |
| • Median Ab titers in BAU/mL (range) | 401 (0–5714) | 1296 (0–45344) | 0.034 |
| SARS-CoV-2-S-RA at 6 months (n = 245) | 30 | 215 | |
| • Median Ab titers in BAU/mL (range) | 202 (0–5714) | 1854 (0–95334) | 0.001 |
| SARS-CoV-2-S-RA at 12 months (n = 191) | 7 | 184 | |
| • Median Ab titers in BAU/mL (range) | 1590 (0–6423) | 3705 (0–26859) | 0.13 |
| ASCT | |||
| SARS-CoV-2-S-RA at 3-6 weeks (n = 101) | 21 | 80 | |
| • Median Ab titers in BAU/mL (range) | 2500 (0–5700) | 1040 (0–41600) | 0.2 |
| SARS-CoV-2-S-RA at 3 months (n = 70) | 10 | 60 | |
| • Median Ab titers in BAU/mL (range) | 1279 (0–4602) | 469 (0–23700) | 0.22 |
| SARS-CoV-2-S-RA at 6 months (n = 64) | 13 | 51 | |
| • Median Ab titers in BAU/mL (range) | 2500 (0–5714) | 1844 (0–23426) | 0.9 |
| SARS-CoV-2-S-RA at 12 months (n = 46) | 3 | 43 | |
| • Median Ab titers in BAU/mL (range) | 4475 (435–5000) | 1820 (0–206568) | 0.7 |
Allo-HSCT refers to allogeneic hematopoietic stem cell transplant, ASCT autologous stem cell transplantation, Ab antibody, SARS-CoV-2-S-RASARS-CoV2-reactive antibodies.